Private equity’s growing interest in biotech brings capital and scale - but at what cost to early-stage innovation ?
Our Founding Partner Patrice Mesnier recently contributed to Real Deals on a structural challenge in today’s biotech landscape: the accelerating shift of capital toward late-stage assets, and the potential long-term consequences for scientific discovery.
Read the full article here:
https://realdeals.eu.com/article/capital-injection
Quotes from Oldenburg
“There is a clear risk that capital moves too fast into late-stage biotech. Many private equity funds approach biotech as a financial product, not as scientific exploration. It brings scale but it also drains oxygen from the early-stage ecosystem where real innovation is born”.
“When the money focuses on exits instead of discovery, the pipeline weakens. To secure the next generation of assets, investors will need hybrid models, cooperation between venture capital, private equity and public research, so that early science can survive until it reaches maturity”.
— Patrice Mesnier, Founding Partner